Tezepelumab via APFS ( DrugBank: Tezepelumab )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 98 | Eosinophilic gastrointestinal disease | 1 |
98. Eosinophilic gastrointestinal disease
Clinical trials : 172 / Drugs : 149 - (DrugBank : 39) / Drug target genes : 38 - Drug target pathways : 135
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2022-001294-31-DK (EUCTR) | 22/11/2022 | 04/10/2022 | Efficacy and Safety of Tezepelumab in Patients with Eosinophilic Esophagitis | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) - CROSSING | Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus MedDRA version: 20.1;Level: LLT;Classification code 10064220;Term: Eosinophilic esophagitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Tezepelumab via APFS Product Code: MEDI9929 anti-TSLP mAb (AMG157) INN or Proposed INN: Tezepelumab Other descriptive name: AMG 157 | AstraZeneca AB | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 360 | Phase 3 | United States;Czechia;Slovakia;Greece;Finland;Spain;Austria;Israel;Italy;Canada;Belgium;Brazil;Denmark;Australia;Norway;Germany;Netherlands;China;Japan;New Zealand;Sweden |